BACKGROUND: A previous subgroup analysis of a 12-week, double-blind study demonstrated that losartan significantly lowered proteinuria versus placebo and amlodipine and was well tolerated in children (1-17 years old) with proteinuria secondary to Alport syndrome. The present subgroup analysis of the open-label, extension phase of this study assessed the long-term efficacy and tolerability of losartan versus enalapril. METHODS:Patients who had completed the double-blind study were re-randomized to losartan or enalapril and followed for proteinuria and renal function for up to 3 years. RESULTS:Twenty-seven patients with Alport syndrome were randomized to losartan (0.44-2.23 mg/kg/day; n = 15) or enalapril (0.07-0.72 mg/kg/day; n = 12). The least-squares (LS) mean percent change from week 12 in urinary protein to creatinine ratio (UPr/Cr was +1.1 % in the losartan group versus a further 13.9 % reduction in the enalapril group (GMR [95 % CI] = 1.2 [0.7, 2.0]); the LS mean change from week 12 in estimated glomerular filtration rate (eGFR) was -6.4 ml/min/1.73 m(2) in the losartan group versus -9.1 ml/min/1.73 m(2) in the enalapril group. The adverse event incidence was low and comparable in both treatment groups. CONCLUSIONS: In children with proteinuria secondary to Alport syndrome, losartan maintained proteinuria reduction, andenalapril produced a further proteinuria reduction over the 3-year study period. Both agents were generally well tolerated.
RCT Entities:
BACKGROUND: A previous subgroup analysis of a 12-week, double-blind study demonstrated that losartan significantly lowered proteinuria versus placebo and amlodipine and was well tolerated in children (1-17 years old) with proteinuria secondary to Alport syndrome. The present subgroup analysis of the open-label, extension phase of this study assessed the long-term efficacy and tolerability of losartan versus enalapril. METHODS:Patients who had completed the double-blind study were re-randomized to losartan or enalapril and followed for proteinuria and renal function for up to 3 years. RESULTS: Twenty-seven patients with Alport syndrome were randomized to losartan (0.44-2.23 mg/kg/day; n = 15) or enalapril (0.07-0.72 mg/kg/day; n = 12). The least-squares (LS) mean percent change from week 12 in urinary protein to creatinine ratio (UPr/Cr was +1.1 % in the losartan group versus a further 13.9 % reduction in the enalapril group (GMR [95 % CI] = 1.2 [0.7, 2.0]); the LS mean change from week 12 in estimated glomerular filtration rate (eGFR) was -6.4 ml/min/1.73 m(2) in the losartan group versus -9.1 ml/min/1.73 m(2) in the enalapril group. The adverse event incidence was low and comparable in both treatment groups. CONCLUSIONS: In children with proteinuria secondary to Alport syndrome, losartan maintained proteinuria reduction, and enalapril produced a further proteinuria reduction over the 3-year study period. Both agents were generally well tolerated.
Authors: Oliver Gross; Christoph Licht; Hans J Anders; Bernd Hoppe; Bodo Beck; Burkhard Tönshoff; Britta Höcker; Simone Wygoda; Jochen H H Ehrich; Lars Pape; Martin Konrad; Wolfgang Rascher; Jörg Dötsch; Dirk E Müller-Wiefel; Peter Hoyer; Bertrand Knebelmann; Yves Pirson; Jean-Pierre Grunfeld; Patrick Niaudet; Pierre Cochat; Laurence Heidet; Said Lebbah; Roser Torra; Tim Friede; Katharina Lange; Gerhard A Müller; Manfred Weber Journal: Kidney Int Date: 2011-12-14 Impact factor: 10.612
Authors: Nicholas J A Webb; Chun Lam; Shahnaz Shahinfar; Juergen Strehlau; Thomas G Wells; Gilbert W Gleim; Céline Le Bailly De Tilleghem Journal: Nephrol Dial Transplant Date: 2011-02-01 Impact factor: 5.992
Authors: Nicholas J A Webb; Shahnaz Shahinfar; Thomas G Wells; Rachid Massaad; Gilbert W Gleim; Emanuela P Santoro; Christine M Sisk; Chun Lam Journal: Kidney Int Date: 2012-06-27 Impact factor: 10.612
Authors: Nicholas J A Webb; Chun Lam; Tom Loeys; Shahnaz Shahinfar; Juergen Strehlau; Thomas G Wells; Emanuela Santoro; Denise Manas; Gilbert W Gleim Journal: Clin J Am Soc Nephrol Date: 2010-01-14 Impact factor: 8.237
Authors: Elke Wühl; Antonella Trivelli; Stefano Picca; Mieczyslaw Litwin; Amira Peco-Antic; Aleksandra Zurowska; Sara Testa; Augustina Jankauskiene; Sevinc Emre; Alberto Caldas-Afonso; Ali Anarat; Patrick Niaudet; Sevgi Mir; Aysin Bakkaloglu; Barbara Enke; Giovanni Montini; Ann-Margret Wingen; Peter Sallay; Nikola Jeck; Ulla Berg; Salim Caliskan; Simone Wygoda; Katharina Hohbach-Hohenfellner; Jiri Dusek; Tomasz Urasinski; Klaus Arbeiter; Thomas Neuhaus; Jutta Gellermann; Dorota Drozdz; Michel Fischbach; Kristina Möller; Marianne Wigger; Licia Peruzzi; Otto Mehls; Franz Schaefer Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: Marijn F Stokman; Kirsten Y Renkema; Rachel H Giles; Franz Schaefer; Nine V A M Knoers; Albertien M van Eerde Journal: Nat Rev Nephrol Date: 2016-07-04 Impact factor: 28.314
Authors: Sang Heon Suh; Hong Sang Choi; Chang Seong Kim; In Jin Kim; Seong Kwon Ma; James W Scholey; Soo Wan Kim; Eun Hui Bae Journal: Int J Mol Sci Date: 2019-08-06 Impact factor: 5.923
Authors: H Trimarchi; R Canzonieri; A Muryan; A Schiel; A Araoz; M Paulero; J Andrews; T Rengel; M Forrester; F Lombi; V Pomeranz; R Iriarte; E Zotta Journal: Case Rep Nephrol Date: 2016-01-28
Authors: Sang Heon Suh; Hong Sang Choi; Chang Seong Kim; In Jin Kim; Hyunju Cha; Joong Myung Cho; Seong Kwon Ma; Soo Wan Kim; Eun Hui Bae Journal: Int J Mol Sci Date: 2020-02-21 Impact factor: 5.923
Authors: Soo Wan Kim; Eun Hui Bae; Hong Sang Choi; In Jin Kim; Chang Seong Kim; Seong Kwon Ma; James W Scholey Journal: Sci Rep Date: 2020-03-06 Impact factor: 4.379